GlaxoSmithKline Pharmaceuticals vs Eli Lilly and: Fair Value & Quality
Both stocks run through our valuation models. Here is how GlaxoSmithKline Pharmaceuticals (GLAXO) and Eli Lilly and (LLY) compare, as of Oct 1, 2026.
Head-to-head numbers
Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.
betterweakerfor reference, not scored
Eli Lilly and leads: 6 to 8 metric wins.
n/a = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.
▲above the price, more than 15% above ●close to the price, 85% to 115% of the price ▼below the price, more than 15% below
| Model family | GlaxoSmithKline PharmaceuticalsPrice ₹2,769 | Eli Lilly andPrice $1,157 |
|---|---|---|
| DCF Models | ▼−64.9%below the price₹972 | ▼−70.2%below the price$345 |
| Earnings-Based | ▼−77.7%below the price₹618 | ▼−79.4%below the price$239 |
| Dividend Discount | ▼−79.1%below the price₹579 | ▼−90.0%below the price$115 |
| Multiples | ▼−64.8%below the price₹975 | ▼−69.1%below the price$358 |
| Asset-Based | ▼−96.8%below the price₹89.68 | ▼−98.3%below the price$19.94 |
| Growth DCF | ▼−69.6%below the price₹843 | ▼−83.0%below the price$197 |
| Economic Profit | ▼−81.7%below the price₹507 | ▼−79.6%below the price$237 |
| Growth Earnings | ▼−60.7%below the price₹1,088 | ▼−67.6%below the price$375 |
| Minimum | ▼−96.8%below the price₹89.68 | ▼−98.3%below the price$19.94 |
| Maximum | ▼−60.7%below the price₹1,088 | ▼−67.6%below the price$375 |
| Median | ▼−73.6%below the price₹730 | ▼−79.5%below the price$238 |
| Geometric mean | ▼−78.8%below the price₹587 | ▼−84.3%below the price$182 |
Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.
GlaxoSmithKline Pharmaceuticals: 25 of 25 models see the stock below the current price.
Eli Lilly and: 26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
GlaxoSmithKline Pharmaceuticals · Health Care
Eli Lilly and · Health Care
Bottom line
As of Oct 1, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: GlaxoSmithKline Pharmaceuticals trades at ₹2,769 versus a fair value of ₹905 (−67.3%), while Eli Lilly and trades at $1,157 versus $749 (−35.3%).
GlaxoSmithKline Pharmaceuticals has the higher quality score (80/100).
Open Eli Lilly and live analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to GlaxoSmithKline Pharmaceuticals
Eli Lilly and vs UnitedHealth GroupMicrosoft vs NvidiaApple vs MicrosoftMicrosoft vs Taiwan Semiconductor ManufacturingSee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.